Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cingulate Inc (CING – Research Report) and Genenta Science SpA Sponsored ADR (GNTA – Research Report).
Cingulate Inc (CING)
Maxim Group analyst Naz Rahman maintained a Hold rating on Cingulate Inc yesterday. The company’s shares closed last Friday at $0.86, close to its 52-week low of $0.75.
According to TipRanks.com, Rahman is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The the analyst consensus on Cingulate Inc is currently a Hold rating.
See today’s best-performing stocks on TipRanks >>
Genenta Science SpA Sponsored ADR (GNTA)
In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Genenta Science SpA Sponsored ADR, with a price target of $25.00. The company’s shares closed last Friday at $3.10.
According to TipRanks.com, Pantginis is a 5-star analyst with an average return of
Genenta Science SpA Sponsored ADR has an analyst consensus of Moderate Buy, with a price target consensus of $25.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CING:
- Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update
- Cingulate reports Q1 EPS (60c) vs ($7.08) last year
- Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
- Cingulate to Participate in Planet MicroCap Showcase: Vegas 2024
- Cingulate Inc. Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
